Zepbound

News

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.

News

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.